Try a new search

Format these results:

Searched for:



Total Results:


The Rise of Eating Disorders During COVID-19 and the Impact on Treatment [Letter]

Reed, Jace; Ort, Katherine
PMID: 34780989
ISSN: 1527-5418
CID: 5048982

Improving Communication with LGBTQ Patients: A Pilot Curriculum During the Psychiatry Clerkship

Fadus, Matthew C; Peterson, Neal K; Jilich, Celeste L; Kantor, Edward M; Beckert, David R; Reed, Jace M; Valadez, Emilio A; Brendle, Timothy A
PMID: 31820369
ISSN: 1545-7230
CID: 4552792

Nail irregularities associated with Sézary syndrome [Case Report]

Park, Katherine; Reed, Jace; Talpur, Rakhshandra; Duvic, Madeleine
Sézary syndrome (SS) is the leukemic form of cutaneous T-cell lymphoma (CTCL) and can be associated with various nail irregularities, though they are infrequently reported. In this retrospective study, we reviewed medical records from a CTCL clinic database at the University of Texas MD Anderson Cancer Center (Houston, Texas) for reported nail abnormalities in patients with a diagnosis of SS. Findings for 2 select cases are described in more detail and are compared to prior case reports to establish a comprehensive list of nail irregularities that have been associated with SS.
PMID: 31116823
ISSN: 2326-6929
CID: 4552782

Levetiracetam-induced transaminitis in a young male with traumatic brain injury [Case Report]

Rachamallu, Vivekananda; Song, Michael M; Reed, Jace M; Aligeti, Manish
Levetiracetam is a commonly prescribed antiepileptic drug for seizure prophylaxis in patients with traumatic brain injury (TBI). Levetiracetam metabolism has been reported to be non-dependent on hepatic cytochrome P450 (CYP450) isoenzyme system. Furthermore, levetiracetam and its metabolites are reported to be eliminated from systemic circulation via renal excretion. Therefore, due to its well-known renal clearance mechanism with no dosage adjustments recommended for hepatic impairment, levetiracetam is often chosen as the drug of choice in patients with suspected or ongoing hepatic dysfunction. Furthermore, monitoring of liver enzymes is often not considered to be critical in levetiracetam therapy. However, hepatotoxicity is still possible with levetiracetam. Here, we report on an 18-year-old male with TBI who developed transaminitis with levetiracetam therapy which resolved following the discontinuation of levetiracetam. A close monitoring of liver enzymes and early recognition of hepatotoxicity is still necessary and critical to preventing major sequelae stemming from levetiracetam-induced hepatotoxicity.
PMID: 29744119
ISSN: 2053-8855
CID: 4552772

An unusual case of cytotoxic peripheral T-cell lymphoma [Case Report]

Wang, Casey; Reusser, Nicole; Shelton, Megan; Reed, Jace; Doan, Hung; Torres-Cabala, Carlos Antonio; Dabaja, Bouthaina; Duvic, Madeleine
PMID: 27051746
ISSN: 2352-5126
CID: 4552762